Teva Pharmaceuticals

Teva Pharmaceuticals
Share

Teva Pharmaceuticals

 •  January 15

JERUSALEM--(BUSINESS WIRE)--Jan. 15, 2018-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved the use of TRISENOX® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)...

Teva Pharmaceuticals

 •  December 27, 2017

JERUSALEM--(BUSINESS WIRE)--Dec. 27, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced the exclusive launch of a generic version of Reyataz®1 (atazanavir) capsules in the U.S. Atazanavir sulfate capsules are a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of...

Teva Pharmaceuticals

 •  December 15, 2017

JERUSALEM--(BUSINESS WIRE)--Dec. 15, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive launch of generic Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg in the U.S. Tenofovir disoproxil fumarate tablets are a nucleotide analog HIV-1 reverse transcriptase inhibitor indicated in combination with...

Teva Pharmaceuticals

 •  November 29, 2017

Marks the first Phase III chronic migraine data to be published within anti-CGRP class JERUSALEM--(BUSINESS WIRE)--Nov. 29, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the publication of data from the pivotal Phase III HALO study evaluating the efficacy, safety and tolerability of two subcutaneous dose...

Teva Pharmaceuticals

 •  November 1, 2017

Teva receives $1.1 billion cash proceeds to progress repayment of term loan debt Closures mark first completion of planned divestiture of non-core assets to enable greater focus on core Specialty therapeutic areas of CNS and Respiratory JERUSALEM--(BUSINESS WIRE)--Nov. 1, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today...

Teva Pharmaceuticals

 •  October 4, 2017

JERUSALEM--(BUSINESS WIRE)--Oct. 4, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today commented that any launch by Mylan of a generic version of COPAXONE® 40mg/ml (glatiramer acetate) prior to final resolution of the pending patent appeals and other patent litigation should be considered an “at-risk” launch, which could...

Teva Pharmaceuticals

 •  September 25, 2017

JERUSALEM--(BUSINESS WIRE)--Sep. 25, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the reintroduction of the generic equivalent to Depo-Provera®1 Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL, in the United States. Medroxyprogesterone acetate injectable suspension is a...

Teva Pharmaceuticals

 •  March 6, 2017

JERUSALEM--(BUSINESS WIRE)--Mar. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37th Annual Healthcare Conference in Boston, MA. When: Wednesday, March 8, 2017 at 9:20 AM ET Who: Marcelo Bigal, M.D. Ph.D., SVP, Head of Global Specialty Development, Mike Derkacz, SVP, Head...

Teva Pharmaceuticals

 •  February 2, 2017

JERUSALEM--(BUSINESS WIRE)--Feb. 2, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that it has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market the generic version of Novo Nordisk's Victoza® (liraglutide) injection, in the U.S. Victoza® is...

Teva Pharmaceuticals

 •  December 6, 2016

JERUSALEM--(BUSINESS WIRE)--Dec. 6, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® (glatiramer acetate injection) 20 mg/mL. The product was originally authorized...